BR112021016912A2 - Composto de benzoindazolona e intermediário do mesmo - Google Patents

Composto de benzoindazolona e intermediário do mesmo

Info

Publication number
BR112021016912A2
BR112021016912A2 BR112021016912A BR112021016912A BR112021016912A2 BR 112021016912 A2 BR112021016912 A2 BR 112021016912A2 BR 112021016912 A BR112021016912 A BR 112021016912A BR 112021016912 A BR112021016912 A BR 112021016912A BR 112021016912 A2 BR112021016912 A2 BR 112021016912A2
Authority
BR
Brazil
Prior art keywords
compound
benzoindazolone
nqo1
present
diasteromer
Prior art date
Application number
BR112021016912A
Other languages
English (en)
Inventor
Ju Lee Eun
Seok Ko In
Seong LEE Whee
Original Assignee
Lmito Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lmito Therapeutics Inc filed Critical Lmito Therapeutics Inc
Publication of BR112021016912A2 publication Critical patent/BR112021016912A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

composto de benzoindazolona e intermediário do mesmo. campo técnico. a presente invenção refere-se a um composto de benzoindazolona ou um sal, hidrato, solvato, enantiômero, diasterômero, tautômero ou pró-fármaco farmaceuticamente aceitável do mesmo e a um intermediário do mesmo. um composto, de acordo com a presente invenção, é usado como um substrato para nqo1 para facilitar uma reação redox de nqo1 e, assim, espera-se que seja desenvolvido como um medicamento para prevenir ou tratar doenças inflamatórias.
BR112021016912A 2019-02-28 2020-02-20 Composto de benzoindazolona e intermediário do mesmo BR112021016912A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190023942A KR102201768B1 (ko) 2019-02-28 2019-02-28 벤조인다졸론 화합물 및 그 용도
PCT/KR2020/002459 WO2020175851A1 (ko) 2019-02-28 2020-02-20 벤조인다졸론 화합물 및 그 제조 중간체

Publications (1)

Publication Number Publication Date
BR112021016912A2 true BR112021016912A2 (pt) 2021-11-03

Family

ID=72239783

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021016912A BR112021016912A2 (pt) 2019-02-28 2020-02-20 Composto de benzoindazolona e intermediário do mesmo

Country Status (9)

Country Link
US (1) US20220144780A1 (pt)
EP (1) EP3932909A4 (pt)
JP (1) JP7359463B2 (pt)
KR (1) KR102201768B1 (pt)
CN (1) CN113454068A (pt)
AU (1) AU2020229601B2 (pt)
BR (1) BR112021016912A2 (pt)
CA (1) CA3129943A1 (pt)
WO (1) WO2020175851A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102506406B1 (ko) * 2021-04-19 2023-03-07 주식회사 삼양홀딩스 케토-엔올 변환체 약물을 함유하는 생체 시료의 전처리 방법 및 이에 의하여 전처리된 시료, 및 이 전처리 시료에 대한 정량 분석 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1000060A1 (en) * 1997-07-09 2000-05-17 AstraZeneca UK Limited Novel compounds
KR20080099174A (ko) * 2007-05-07 2008-11-12 주식회사 머젠스 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물
WO2015102371A1 (ko) * 2013-12-30 2015-07-09 주식회사 케이티앤지생명과학 1,2 나프토퀴논 유도체 및 이의 제조방법
KR102005068B1 (ko) * 2015-03-27 2019-07-30 주식회사 휴엔 1,2 나프토퀴논 유도체 및 이의 제조방법

Also Published As

Publication number Publication date
EP3932909A4 (en) 2022-12-14
KR20200105165A (ko) 2020-09-07
AU2020229601B2 (en) 2022-09-15
WO2020175851A1 (ko) 2020-09-03
CA3129943A1 (en) 2020-09-03
KR102201768B1 (ko) 2021-01-12
JP2022522701A (ja) 2022-04-20
EP3932909A1 (en) 2022-01-05
CN113454068A (zh) 2021-09-28
JP7359463B2 (ja) 2023-10-11
AU2020229601A1 (en) 2021-09-16
US20220144780A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
ECSP21008112A (es) Compuestos de pirrolotriazina como inhibidores de tam
SV2018005742A (es) Inhibidores de mcl-1 macrocíclicos para tratar el cáncer
BR112018074621A2 (pt) derivados de pirazolopirimidina como inibidores de quinase
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
BR112015016793A2 (pt) compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
BR112014026643A2 (pt) derivados de imidazotiadiazol e imidazopirazina como inibidores de receptor 4 ativado por protease (par4) para o tratamento de agregação de plaqueta
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
MD4684B1 (ro) Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
EA202090052A1 (ru) Содержащие имидазол ингибиторы alk2 киназы
BR112016024936A2 (pt) moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
BR112017008312A2 (pt) novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms)
CL2022000005A1 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
BR112021022378A2 (pt) Derivado de tetraidroisoquinolina substituído como um modulador alostérico d1 positivo
BR112021022255A2 (pt) Composto usado como inibidor de quinase e aplicação do mesmo
BR112016006970A2 (pt) enzalutamida em combinação com afuresertib para o tratamento de câncer
BR112023012947A2 (pt) Inibidores de lrrk2
BR112017015744A2 (pt) composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: LMITO THERAPEUTICS INC (KR)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]